Bayer Beats The Market In 2021 And Has High Hopes For 2022
Bayer Consumer Health posted sales up 6.5% in 2021 as strong demand for supplements and successful launches helped it grow faster than the global market. The company believes it can deliver up to 5% sales growth in 2022 driven by the upcoming launch of Astepro Allergy in the US and the return of the cough & cold category.
You may also be interested in...
Activist investors are pushing for a break-up of Bayer's conglomerate structure and the sale of its Consumer Health division. It will be up to incoming CEO Bill Anderson to make the call.
Major Europe-based consumer health players Sanofi, Reckitt, GSK and Bayer feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q1 2022 results over the coming weeks.
A round-up of the latest European consumer health business news: Norway's Orkla strengthens its supplements offering with acquisition of UK's Healthspan; Bayer makes investment commitment to German Consumer Health operation; and Ipsen strikes a deal to promote brands in the Baltics.